COCP
Cocrystal PharmaยทNASDAQ
--
--(--)
--
--(--)
COCP Profile
Cocrystal Pharma, Inc.
A clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus
19805 North Creek Parkway, Bothell, WA 98011
--
Cocrystal Pharma, Inc., was incorporated in Delaware on January 2, 2014. Its main business is the development of new drugs for the treatment of human viral diseases. Since investing in 2008, Cocrystal Pharma, Inc., has been committed to developing novel technologies and methods to create best-in-class antiviral drugs. The company's focus is on pursuing the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prevention of viral diseases in humans. The company plans to use their infrastructure and expertise in these areas to focus research and development efforts on viral replication inhibitors.
